Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03699579

Enrollment

Registered

2018-10-09

Start date

2019-02-22

Completion date

2019-06-23

Last updated

2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma, Renal Cell Carcinoma Metastatic

Keywords

advanced or metastatic renal cell carcinoma (RCC)

Brief summary

This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with confirmed diagnosis of clear-cell renal cell carcinoma * Patients with evidence of metastatic disease * Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib * Patients who received care at the selected medical centers, utilizing the National Health Insurance (NHI) reimbursed system at the time of the disease

Exclusion criteria

* Patients enrolled in any clinical trial involving anti-cancer therapy * Pregnant woman

Design outcomes

Primary

Measure	Time frame
Medication usage	From start point for 2.5 months
Treatment's duration	From start point for 2.5 months

Secondary

Measure	Time frame	Description
Cost of medication used	From start point for 2.5 months	—
Costs of adverse event management	From start point for 2.5 months	(total calculated costs attributed to Adverse Effects (AEs) management according to the attached list of adverse events
Frequency of health resource usage	From start point for 2.5 months	Outpatient department visits, CT scan, blood test number and types
Cost of health resource usage	From start point for 2.5 months	Outpatient department visits, CT scan, blood test number and types

Countries

Taiwan

Outcome results